Editorial · 31 Dec 2025
Research articlePublished 27 Nov 2018
Safety of Extended Infusion Piperacillin-tazobactam Plus Vancomycin Versus Standard Infusion Piperacillin-tazobactam Plus Vancomycin in General Medicine Patients with a Diagnosis of Healthcare Associated Pneumonia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: The primary safety objective is Acute Kidney Injury (AKI), defined as an increase in serum creatinine of at least 0.5 mg/dL or a 50% increase in serum creatinine from baseline at any time during antibiotic therapy. The objective of this study is to assess safety of Extended Infusion Piperacillin-tazobactam (EIPT) and vancomycin therapy versus Standard Infusion Piperacillin-tazobactam (SIPT) and vancomycin in general medicine patients, and to evaluate if one treatment modality predisposes patients to a greater risk of nephrotoxicity. Setting: Data from a large academic medical center was analyzed over a 3 month period pre and post implementation of extended infusion piperacillin-tazobactam protocol. Design: A retrospective analysis was conducted comparing patients admitted to the hospital with a diagnosis of Healthcare Associated Pneumonia (HCAP) who received EIPT plus vancomycin versus SIPT plus vancomycin. Patients: Adult hospitalized patients on combination therapy with two or more Serum Creatinine (SCr) measurements were included. Patients were excluded if they are less than 18 years of age, are pregnant, or if they are on any form of dialysis including continuous renal replacement therapy. Conclusion: A total of 241 patients were evaluated for AKI. Safety outcomes were compared between the two treatment groups and contributing factors for developing AKI were also assessed. The incidence of AKI was significantly higher in the SIPT and vancomycin group (20.0%) compared with the EIPT and vancomycin group (10.0%) in the analysis (p=0.033). There were no significant differences in the baseline characteristics between the groups with the exception of a higher percentage of patients with a diagnosis of hypertension in the EIPT and vancomycin group (p<0.05).
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Research & Reviews: Journal of Hospital and Clinical Pharmacy.
Editorial · 31 Dec 2025
Clinical Guidelines: Standardizing Care for Improved Patient Outcomes
Editorial · 31 Dec 2025
Quality Improvement and Evidence-Based Practice: Enhancing Healthcare Outcomes
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalResearch & Reviews: Journal of Hospital and Clinical Pharmacy
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kati J Khouri”
- BylineArticles whose byline prints “Joseph A Levato”
- BylineArticles whose byline prints “Rolla T Sweis”